Viatris Inc vs Verizon Communications Inc — how do they compare? Viatris Inc trades at $17.38 (market cap $20.03B), while Verizon Communications Inc trades at $42.27 (market cap $192.57B). The key difference: Verizon Communications Inc is far larger — about 9.6× Viatris Inc's market cap, and Verizon Communications Inc pays the higher dividend (6.11%). Which is the better fit depends on your goals — on Pluang, investors hold Viatris Inc for 57 Days and Verizon Communications Inc for 109 Days on average.
| VTRS | VZ | |
|---|---|---|
Market Cap | $20.03B | $192.57B |
Volume | 14,109,977 | 20,940,094 |
Sector | Health | Media |
52-Week High | $18.27 | $51.45 |
52-Week Low | $9.74 | $38.40 |
Typical Hold Time | 57 Days | 109 Days |
Enterprise Value | $32.15B | $379.28B |
Dividend Yield | 2.75% | 6.11% |
Signals from Pluang's Aura AI — not financial advice
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal supported by moving averages and oversold RSI levels. The company shows consistent earnings beats with Q2 2026 EPS of $0.69 exceeding expectations, while maintaining strong operational cash flow of $2.32B in 2025. Recent developments include FDA approval for WAKIX in Japan and continued recognition as a top employer.
Despite negative net margins, Viatris demonstrates improving cash flow trends and strategic portfolio optimization. The stock offers 27% upside to consensus price target of $22.17, though investors face risks from debt levels and competitive pressures in the generic drug market. Deleveraging progress and pipeline advancements support potential re-rating.
Verizon trades at $45.77, down 0.46% today, with a bearish technical outlook despite recent earnings beats. The stock shows solid fundamentals with a P/E of 12.07, ROE of 15.63%, and consistent dividend payments. Recent news highlights Verizon's joint venture with AT&T and T-Mobile to expand satellite connectivity and the election of Charles Phillips to the board. Cash flow improved significantly in 2025 with net cash flow of $14.9 billion.
Verizon offers value with reasonable valuation metrics and strong cash flow generation supporting its dividend. However, technical indicators signal bearish momentum, and revenue growth remains modest. The stock faces competitive pressures in the telecom sector and carries substantial long-term debt of $121.38 billion. Analyst consensus is mixed with 37.7% buy ratings but a price target of $48.58 suggesting modest upside potential.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →Verizon Communications Inc. is an integrated telecommunications company that provides wire line voice and data services, wireless services, Internet services, and published directory information. The Company also provides network services for the federal government including business phone lines, data services, telecommunications equipment, and payphones.
Read more on VZ →